Assessment of Change in Atherosclerotic Plaque by Serial CCTA (ACROSS)
Sponsor: Chong Kun Dang Pharmaceutical Corp.
This observational or N/A phase trial investigates Coronary Arteriosclerosis and Coronary Artery Disease and is currently ongoing. Chong Kun Dang Pharmaceutical Corp. leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Dec 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jul 2018 — Dec 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chong Kun Dang Pharmaceutical Corp.
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .